Published in J Immunol on August 15, 2007
MHC class I assembly: out and about. Trends Immunol (2008) 1.29
Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors. PLoS One (2011) 1.16
Designing CD8+ T cell vaccines: it's not rocket science (yet). Curr Opin Immunol (2010) 1.13
Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates. PLoS One (2012) 0.97
Minicircle DNA is superior to plasmid DNA in eliciting antigen-specific CD8+ T-cell responses. Mol Ther (2013) 0.93
DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults. Clin Vaccine Immunol (2012) 0.91
Optimization of intradermal vaccination by DNA tattooing in human skin. Hum Gene Ther (2009) 0.91
Mechanisms of immunization against cancer using chimeric antigens. Mol Ther (2008) 0.85
Stable antigen is most effective for eliciting CD8+ T-cell responses after DNA vaccination and infection with recombinant vaccinia virus in vivo. J Virol (2012) 0.81
Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines. Gene Ther (2015) 0.78
Long-peptide therapeutic vaccination against CRPV-induced papillomas in HLA-A2.1 transgenic rabbits. Trials Vaccinol (2014) 0.76
Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in Pten(LoxP/LoxP);Braf(CA/+) Mice. Int J Mol Sci (2016) 0.75
Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice. J Virol (2016) 0.75
B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines. Oncotarget (2016) 0.75
Delivery of Exogenous Antigens to Induce Cytotoxic CD8+ T Lymphocyte Responses. J Biomed Biotechnol (2010) 0.75
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
Design and use of conditional MHC class I ligands. Nat Med (2006) 3.01
The generation of protective memory-like CD8+ T cells during homeostatic proliferation requires CD4+ T cells. Nat Immunol (2006) 2.96
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med (2010) 2.92
Heterogeneous differentiation patterns of individual CD8+ T cells. Science (2013) 2.54
Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat Protoc (2006) 2.47
Cancer immunotherapy--revisited. Nat Rev Drug Discov (2011) 2.26
Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res (2012) 2.08
Antigen bias in T cell cross-priming. Science (2004) 1.82
Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res (2008) 1.81
TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology (2012) 1.78
The cancer antigenome. EMBO J (2012) 1.78
Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7. Proc Natl Acad Sci U S A (2008) 1.77
Recruitment of antigen-specific CD8+ T cells in response to infection is markedly efficient. Science (2009) 1.70
A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med (2005) 1.61
Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol (2006) 1.59
One naive T cell, multiple fates in CD8+ T cell differentiation. J Exp Med (2010) 1.55
In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med (2002) 1.54
Dissecting T cell lineage relationships by cellular barcoding. J Exp Med (2008) 1.53
Adoptive transfer of T-cell immunity. Trends Immunol (2002) 1.50
Tissue-resident memory CD8+ T cells continuously patrol skin epithelia to quickly recognize local antigen. Proc Natl Acad Sci U S A (2012) 1.50
Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation. J Exp Med (2004) 1.46
Differential kinetics of antigen-specific CD4+ and CD8+ T cell responses in the regression of retrovirus-induced sarcomas. J Immunol (2002) 1.46
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother (2014) 1.42
High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat Med (2013) 1.40
Single-cell perforin and granzyme expression reveals the anatomical localization of effector CD8+ T cells in influenza virus-infected mice. Proc Natl Acad Sci U S A (2003) 1.39
Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res (2008) 1.36
Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol (2010) 1.33
Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood (2007) 1.25
T-cell receptor gene therapy of established tumors in a murine melanoma model. J Immunother (2008) 1.24
MHC multimer technology: current status and future prospects. Curr Opin Immunol (2005) 1.24
Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients. Clin Cancer Res (2008) 1.24
Intravital imaging of fluorescent markers and FRET probes by DNA tattooing. BMC Biotechnol (2007) 1.19
Generation of T cell help through a MHC class I-restricted TCR. J Immunol (2006) 1.15
Preclinical development of T cell receptor gene therapy. Curr Opin Immunol (2009) 1.14
Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature (2016) 1.12
Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. Angiogenesis (2009) 1.12
Prospects and limitations of T cell receptor gene therapy. Curr Gene Ther (2011) 1.11
Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res (2008) 1.11
Functional human antigen-specific T cells produced in vitro using retroviral T cell receptor transfer into hematopoietic progenitors. J Immunol (2007) 1.10
TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. J Immunol (2008) 1.08
The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. PLoS One (2009) 1.07
Targeting self-antigens through allogeneic TCR gene transfer. Blood (2006) 1.06
Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J Clin Oncol (2011) 1.04
High-throughput identification of potential minor histocompatibility antigens by MHC tetramer-based screening: feasibility and limitations. PLoS One (2011) 1.03
Requirements for effective antitumor responses of TCR transduced T cells. J Immunol (2008) 1.02
Temporal effects of gamma interferon deficiency on the course of Friend retrovirus infection in mice. J Virol (2002) 1.01
CD8+ T cell tolerance and cancer immunotherapy. J Immunother (2003) 1.01
Specificity and affinity motifs for Grb2 SH2-ligand interactions. Proc Natl Acad Sci U S A (2002) 1.01
The descent of memory T cells. Ann N Y Acad Sci (2011) 1.01
High-throughput T-cell epitope discovery through MHC peptide exchange. Methods Mol Biol (2009) 1.00
TCR repertoires of intratumoral T-cell subsets. Immunol Rev (2014) 1.00
Direct ex vivo detection of HLA-DR3-restricted cytomegalovirus- and Mycobacterium tuberculosis-specific CD4+ T cells. Hum Immunol (2005) 0.99
TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008. Cancer Immunol Immunother (2009) 0.99
Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib. Acta Oncol (2010) 0.99
Discovering naturally processed antigenic determinants that confer protective T cell immunity. J Clin Invest (2013) 0.99
Analysis of autoreactive CD4 T cells in experimental autoimmune encephalomyelitis after primary and secondary challenge using MHC class II tetramers. J Immunol (2004) 0.97
Prospects and limitations of T cell receptor gene therapy. Curr Gene Ther (2005) 0.97
Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). Acta Oncol (2013) 0.95
Class I major histocompatibility complexes loaded by a periodate trigger. J Am Chem Soc (2009) 0.95
An inducible caspase 9 safety switch can halt cell therapy-induced autoimmune disease. J Immunol (2008) 0.94
Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates. Vaccine (2008) 0.94
Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha. Cancer Immunol Immunother (2011) 0.92
T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. Clin Cancer Res (2011) 0.92
Generation of peptide MHC class I monomers and multimers through ligand exchange. Curr Protoc Immunol (2009) 0.92
Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. Eur J Cancer (2005) 0.91
Optimization of intradermal vaccination by DNA tattooing in human skin. Hum Gene Ther (2009) 0.91
Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma. J Clin Oncol (2013) 0.90
T-cell receptor gene therapy: critical parameters for clinical success. J Invest Dermatol (2011) 0.90
Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. Virology (2002) 0.90
Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients. J Immunother (2007) 0.89
Blockade of TGF-β signaling greatly enhances the efficacy of TCR gene therapy of cancer. J Immunol (2013) 0.89
The transcription factor Spi-B regulates human plasmacytoid dendritic cell survival through direct induction of the antiapoptotic gene BCL2-A1. Blood (2012) 0.89
The impact of self-tolerance on the polyclonal CD8+ T cell repertoire. J Immunol (2004) 0.88
UV-induced ligand exchange in MHC class I protein crystals. J Am Chem Soc (2009) 0.88
Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs. J Virol (2002) 0.87